Matches in SemOpenAlex for { <https://semopenalex.org/work/W2171275210> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2171275210 abstract "Abstract 1795 Introduction. The combination of fludarabine and cyclophosphamide (FC) has become the core combination of modern frontline chemotherapy for fit and young B-CLL patients (pts). Recently the association with rituximab to FC (IV administration) has been shown to increase the response and extend both progression free survival (PFS) and overall survival (OS) in untreated pts (Hallek et al., Lancet 2010). So far few data are available concerning the very long term outcome of pts treated by FC containing regimen. Methods. We previously reported a prospective phase II trial (Cazin et al., BJH 2008) of the oral combination of FC over 5 days in 75 patients with untreated B-CLL and less than 66 years old. The study was conducted between October 1999 and February 2001. Briefly, oral FC then demonstrated high efficacy with overall response rate (ORR) and complete response (CR) rate of 80% and 53% respectively despite the absence of rituximab in this regimen. We here propose to examine 10-year end points of progression-free survival (PFS), overall survival (OS), impact of genomic features, and risk of therapy-related myeloid neoplasm (t-MN) by updating survival data of all the pts incuded in this trial. Results. With a median follow-up of 10.7 years, the median 10-year OS was 51.7%. Responders presented better 10-year OS than non-responders (57% vs. 38%, p=0.031) but quality of response (CR vs. PR) did not significantly impact 10-year OS. A major prognostic impact of IGVH mutational status could be observed since 10-year OS was 81% for mutated patients vs . 44% for unmutated pts (p=0.012). The median 10-year PFS was 30% and clearly influenced by the mutational status (50% if mutated profile vs. 12% if unmutated profile, p=0.02). However there is no trend of a plateau and even long term responding patients still relapse with time. Finally, only one patient developed t-MN but 9 others presented solid neoplasms. Conclusion. Long-term follow-up of B-CLL patients prospectively treated in a phase II clinical trial demonstrates extended OS and PFS with oral FC without high risk of t-MN. Disclosures: No relevant conflicts of interest to declare." @default.
- W2171275210 created "2016-06-24" @default.
- W2171275210 creator A5017512905 @default.
- W2171275210 creator A5027678665 @default.
- W2171275210 creator A5037366819 @default.
- W2171275210 creator A5044409234 @default.
- W2171275210 creator A5045965285 @default.
- W2171275210 creator A5052071966 @default.
- W2171275210 creator A5065987951 @default.
- W2171275210 creator A5067560032 @default.
- W2171275210 creator A5071717482 @default.
- W2171275210 date "2011-10-01" @default.
- W2171275210 modified "2023-10-06" @default.
- W2171275210 title "5.32 Long-term Outcome of B-CLL Patients Treated in a Prospective Trial Evaluating Combination of Oral Fludarabine and Cyclophosphamide as Frontline Therapy" @default.
- W2171275210 doi "https://doi.org/10.1016/j.clml.2011.09.186" @default.
- W2171275210 hasPublicationYear "2011" @default.
- W2171275210 type Work @default.
- W2171275210 sameAs 2171275210 @default.
- W2171275210 citedByCount "0" @default.
- W2171275210 crossrefType "journal-article" @default.
- W2171275210 hasAuthorship W2171275210A5017512905 @default.
- W2171275210 hasAuthorship W2171275210A5027678665 @default.
- W2171275210 hasAuthorship W2171275210A5037366819 @default.
- W2171275210 hasAuthorship W2171275210A5044409234 @default.
- W2171275210 hasAuthorship W2171275210A5045965285 @default.
- W2171275210 hasAuthorship W2171275210A5052071966 @default.
- W2171275210 hasAuthorship W2171275210A5065987951 @default.
- W2171275210 hasAuthorship W2171275210A5067560032 @default.
- W2171275210 hasAuthorship W2171275210A5071717482 @default.
- W2171275210 hasConcept C126322002 @default.
- W2171275210 hasConcept C143998085 @default.
- W2171275210 hasConcept C188816634 @default.
- W2171275210 hasConcept C2776694085 @default.
- W2171275210 hasConcept C2776755627 @default.
- W2171275210 hasConcept C2779263901 @default.
- W2171275210 hasConcept C2779338263 @default.
- W2171275210 hasConcept C2780653079 @default.
- W2171275210 hasConcept C2780739268 @default.
- W2171275210 hasConcept C2781413609 @default.
- W2171275210 hasConcept C71924100 @default.
- W2171275210 hasConcept C90924648 @default.
- W2171275210 hasConceptScore W2171275210C126322002 @default.
- W2171275210 hasConceptScore W2171275210C143998085 @default.
- W2171275210 hasConceptScore W2171275210C188816634 @default.
- W2171275210 hasConceptScore W2171275210C2776694085 @default.
- W2171275210 hasConceptScore W2171275210C2776755627 @default.
- W2171275210 hasConceptScore W2171275210C2779263901 @default.
- W2171275210 hasConceptScore W2171275210C2779338263 @default.
- W2171275210 hasConceptScore W2171275210C2780653079 @default.
- W2171275210 hasConceptScore W2171275210C2780739268 @default.
- W2171275210 hasConceptScore W2171275210C2781413609 @default.
- W2171275210 hasConceptScore W2171275210C71924100 @default.
- W2171275210 hasConceptScore W2171275210C90924648 @default.
- W2171275210 hasLocation W21712752101 @default.
- W2171275210 hasOpenAccess W2171275210 @default.
- W2171275210 hasPrimaryLocation W21712752101 @default.
- W2171275210 hasRelatedWork W1990815726 @default.
- W2171275210 hasRelatedWork W2078045353 @default.
- W2171275210 hasRelatedWork W2171004514 @default.
- W2171275210 hasRelatedWork W2295513998 @default.
- W2171275210 hasRelatedWork W2473105612 @default.
- W2171275210 hasRelatedWork W2548157737 @default.
- W2171275210 hasRelatedWork W2558553681 @default.
- W2171275210 hasRelatedWork W2558604142 @default.
- W2171275210 hasRelatedWork W2560547360 @default.
- W2171275210 hasRelatedWork W2562143240 @default.
- W2171275210 hasRelatedWork W2565510052 @default.
- W2171275210 hasRelatedWork W2578796292 @default.
- W2171275210 hasRelatedWork W2582014052 @default.
- W2171275210 hasRelatedWork W2586736954 @default.
- W2171275210 hasRelatedWork W2586908392 @default.
- W2171275210 hasRelatedWork W2592880580 @default.
- W2171275210 hasRelatedWork W2738464324 @default.
- W2171275210 hasRelatedWork W2981164630 @default.
- W2171275210 hasRelatedWork W3029146370 @default.
- W2171275210 hasRelatedWork W610064742 @default.
- W2171275210 isParatext "false" @default.
- W2171275210 isRetracted "false" @default.
- W2171275210 magId "2171275210" @default.
- W2171275210 workType "article" @default.